With Congress trying to figure out Mylan's business model for the EpiPen, a medical technologies expert and a Seattle doctor have been physically taking apart the auto-injectors to find out exactly how the device has changed since Mylan acquired it, NBC News reported.
Mylan CEO Heather Bresch testified last week that it invested more than $1 billion enhancing the product, which is one of the reason the Epipen's price has risen from $100 to $600.
After a Seattle doctor cut open EpiPens from before and after Mylan's upgrades, NBC News sent versions of the epinephrine auto-injectors to a medical technology consulting firm. Despite seeing safety and graphics upgrades, both found the devices shared a similar "core."
After NBC News sent the firm's results to Mylan, a spokesman for the drugmaker said it was "not familiar with the research referenced in your email" but contended that "anyone who has used the product knows, the epinephrine auto-injector we have in the market today is substantially different than the one we acquired."